Literature DB >> 21735453

Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury.

Satonori Higuchi1, Masanori Kobayashi, Azusa Yano, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi.   

Abstract

Drug-induced liver injury is a growing concern for pharmaceutical companies and patients because numerous drugs have been linked to hepatotoxicity and it is the most common reason for a drug to be withdrawn. Flutamide rarely causes liver dysfunction in humans, and immune allergic reactions have been suggested in some cases. In this study, we investigated the mechanisms of flutamide-induced liver injury in BALB/c mice. Plasma alanine aminotransferase and aspartate aminotransferase levels were significantly increased 3, 6 and 9 h after flutamide (1500 mg kg⁻¹ , p.o.) administration. The biomarker for oxidative stress was not changed, but Th2-dominant immune-related factors, such as interleukin (IL)-4, IL-5, STAT6 and GATA-binding protein (GATA)-3, were induced in flutamide-administered mice. The pre-administration of monoclonal-IL-4 antibody suppressed the hepatotoxicity of flutamide. In addition, we investigated the effect of 13,14-dihydro-15-keto-PGD₂ (DK-PGD₂; 10 µg per mouse, i.p.) administration on flutamide-induced acute liver injury. Coadministration of DK-PGD₂ and flutamide resulted in a significant increase in alanine aminotransferase and a remarkable increase of macrophage inflammatory protein-2. In conclusion, we demonstrated that flutamide-induced acute liver injury is mediated by Th2-dominant immune responses in mice.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735453     DOI: 10.1002/jat.1706

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  5 in total

1.  An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury.

Authors:  Shingo Oda; Yuka Uchida; Michael D Aleo; Petra H Koza-Taylor; Yusuke Matsui; Masanori Hizue; Lisa D Marroquin; Jessica Whritenour; Eri Uchida; Tsuyoshi Yokoi
Journal:  Arch Toxicol       Date:  2020-08-20       Impact factor: 5.153

2.  Adenovirus-mediated dual gene expression of human interleukin-10 and hepatic growth factor exerts protective effect against CCl4-induced hepatocyte injury in rats.

Authors:  Hong Qiu; Yan Yan; Jicheng Xing; Yuerong Zhu; Lin Fang; Xiangrong Cao; Changqing Su
Journal:  Dig Dis Sci       Date:  2012-03-08       Impact factor: 3.199

3.  Interleukin-4 deficiency protects mice from acetaminophen-induced liver injury and inflammation by prevention of glutathione depletion.

Authors:  Daniele Araújo Pires; Pedro Elias Marques; Rafaela Vaz Pereira; Bruna Araújo David; Lindisley Ferreira Gomides; Ana Carolina Fialho Dias; Albená Nunes-Silva; Vanessa Pinho; Denise Carmona Cara; Leda Quercia Vieira; Mauro Martins Teixeira; Gustavo Batista Menezes
Journal:  Inflamm Res       Date:  2013-10-08       Impact factor: 4.575

4.  Thymic stromal lymphopoietin and interleukin-4 mediate the pathogenesis of halothane-induced liver injury in mice.

Authors:  William R Proctor; Mala Chakraborty; Aaron M Fullerton; Midhun C Korrapati; Pauline M Ryan; Kenrick Semple; Jeffrey C Morrison; Julia D Berkson; Lynette S Chea; Qian Yang; Albert P Li; Rosanne Spolski; Erin E West; Yrina Rochman; Warren J Leonard; Mohammed Bourdi; Lance R Pohl
Journal:  Hepatology       Date:  2014-05-20       Impact factor: 17.425

5.  Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.

Authors:  Nury M Steuerwald; David M Foureau; H James Norton; Jie Zhou; Judith C Parsons; Naga Chalasani; Robert J Fontana; Paul B Watkins; William M Lee; K Rajender Reddy; Andrew Stolz; Jayant Talwalkar; Timothy Davern; Dhanonjoy Saha; Lauren N Bell; Huiman Barnhart; Jiezhun Gu; Jose Serrano; Herbert L Bonkovsky
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.